Long term follow-up data of 27939 healthy women with baseline plasma samples in the Women 's Health Study , a randomised trial of 100mg alternate-day aspirin versus placebo , were used to develop competing risks models for individualised prediction of absolute risk reduction of the combination of CVD , cancer and major gastrointestinal bleeding by aspirin .